Tumour vasculature targeting agents in hybrid/conjugate drugs

Targeting tumour vasculature as a cancer treatment

Modelling blood flow and capillary growth in tumours has been the focus of several research groups with the aim of generating theoretical models that can be used to predict biological behaviour within these systems. Since dysfunctional angiogenesis is seen in a wide range of pathological conditions ranging from cardiovascular, to arthritis, to diabetes, it is easy to see how these models may ha...

Therapeutic Targeting and Clinical Assessment of the Tumour Vasculature

Tumour Selective Nuclear Targeting in a Tumour

PROGRESSION MODEL 2 3 Michael S. Nastasie, Helmut Thissen, David A. Jans and Kylie M. Wagstaff 4 Nuclear Signalling Laboratory, Dept. Biochemistry and Molecular Biology, Monash 5 University, Clayton, Victoria 3800, Australia 6 CSIRO Molecular and Health Technologies, Bayview Avenue, Clayton, Victoria 3168, 7 Australia 8 Running Title: Tumour selective nuclear targeting 9 10 *Correspondence shou...

Tubulin-binding dibenz[c,e]oxepines as colchinol analogues for targeting tumour vasculature.

Various methoxy- and hydroxy-substituted dibenz[c,e]oxepines were prepared via the copper(I)-induced coupling of ether-tethered arylstannanes or the dehydrative cyclisation of 1,1'-biphenyl-2,2'-dimethanols, assembled using the Ullmann cross-coupling of ortho-bromoaryl carbonyl compounds. The dibenzoxepines were screened for their ability to inhibit tubulin polymerisation and the in vitro growt...

RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature.

During the past decade, RGD-peptides have become a popular tool for the targeting of drugs and imaging agents to alphavbeta3-integrin expressing tumour vasculature. RGD-peptides have been introduced by recombinant means into therapeutic proteins and viruses. Chemical means have been applied to couple RGD-peptides and RGD-mimetics to liposomes, polymers, peptides, small molecule drugs and radiot...